{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:55:31Z","timestamp":1772117731324,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd006910","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T00:00:00Z","timestamp":1373328000000}}],"reference-count":152,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006910.pub2","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T08:41:18Z","timestamp":1373359278000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer"],"prefix":"10.1002","volume":"2016","author":[{"given":"Theresa A","family":"Lawrie","sequence":"first","affiliation":[{"name":"Royal United Hospital; Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group; Education Centre Bath UK BA1 3NG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bryant","sequence":"additional","affiliation":[{"name":"Newcastle University; Institute of Health & Society; Medical School New Build Richardson Road Newcastle upon Tyne UK NE2 4AX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Cameron","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol NHS Foundation Trust; Department of Clinical Oncology; Bristol Haematology and Oncology Centre Horfield Road Bristol UK BS2 8ED"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Gray","sequence":"additional","affiliation":[{"name":"Musgrove Park Hospital; The Beacon Centre; Taunton Somerset UK TA1 5DA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Morrison","sequence":"additional","affiliation":[{"name":"Musgrove Park Hospital; Department of Gynaecological Oncology; Taunton and Somerset NHS Foundation Trust Taunton Somerset UK TA1 5DA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,9]]},"reference":[{"key":"10.1002\/14651858.CD006910.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Rose P Edwards R Finkler N Seiden M Duska L Krasner C Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC) Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 2007","DOI":"10.1200\/jco.2007.25.18_suppl.lba5529"},{"issue":"5","key":"10.1002\/14651858.CD006910.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/IGC.0b013e3181daaf59","article-title":"Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer","volume":"20","author":"Vergote","year":"2010","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Vergote I Phase 3 study of canfosfamide (TLK 286) plus pegylated liposomal doxorubicin (PLD) vs PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer Journal of Clinical Oncology; 2009 ASCO annual meeting 2009","DOI":"10.1200\/jco.2009.27.15_suppl.5552"},{"issue":"4","key":"10.1002\/14651858.CD006910.pub2-BIB0005|cit4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bjc.2011.593","article-title":"CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial","volume":"106","author":"Alexandre","year":"2012","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0006|cit5","unstructured":"Alexandre J Brown C Priou F De Rauglaudre G Pfisterer J Maenpaa J Should CA 125 still be part of tumour evaluation criteria in ovarian cancer trials? Experience of the GCIG calypso trial Annals of Oncology, 35th ESMO Congress, Milan, Italy 2010 viii 307: abstr. 981P"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0007|cit6","unstructured":"Baumann KH Pujade-Lauraine E Jackisch C Lubbe D du Bois A Brown C Therapy expectations of patients with recurrent platinum-sensitive ovarian cancer-a German substudy of the calypso\/ago-ovar 2.9 trial International Journal of Gynecological Cancer, 17th International Meeting of ESGO 2011"},{"issue":"8","key":"10.1002\/14651858.CD006910.pub2-BIB0008|cit7","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdr583","article-title":"Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial","volume":"23","author":"Brundage","year":"2012","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006910.pub2-BIB0009|cit8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdr441","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","volume":"23","author":"Gladieff","year":"2012","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006910.pub2-BIB0010|cit9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2011.04.019","article-title":"Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial","volume":"122","author":"Joly","year":"2011","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0011|cit10","doi-asserted-by":"crossref","unstructured":"Kurtz J Hilpert F Dorum A Veillard A Elit L Buck M Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial Journal of Clinical Oncology 2010 ASCO Annual Meeting 2010","DOI":"10.1200\/jco.2010.28.15_suppl.5031"},{"issue":"11","key":"10.1002\/14651858.CD006910.pub2-BIB0012|cit11","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/annonc\/mdr001","article-title":"Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study","volume":"22","author":"Kurtz","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0016|cit12","unstructured":"Lee CK Ovar 2.9: A Phase III study compare PLD-doxorubicine-carboplatin (CD) with carboplatin-paclitaxel (CP) in recurrent platin-sensible ovarian cancer. A GCIG study Archives of Gynecology and Obstetrics, Proceedings of the 58th Congress of the German Society for Gynecology and Obstetrics (DGGG) 2011"},{"issue":"17","key":"10.1002\/14651858.CD006910.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/jnci\/djr282","article-title":"Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer","volume":"103","author":"Lee","year":"2011","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD006910.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/bjc.2011.256","article-title":"Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer","volume":"105","author":"Lee","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD006910.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/bjc.2011.364","article-title":"Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer","volume":"105","author":"Lee","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0017|cit16","doi-asserted-by":"crossref","unstructured":"Mahner S Meier W Du Bois A Brown C Lorusso D Ferrero A Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial Journal of Clinical Oncology 2011 ASCO Annual Meeting 2011","DOI":"10.1200\/jco.2011.29.15_suppl.5059"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0018|cit17","doi-asserted-by":"crossref","unstructured":"Marth C Alexandre J Hanker LC Brown C Kaern J Heywood M Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial Journal of Clinical Oncology 2011 ASCO Annual Meeting 2011","DOI":"10.1200\/jco.2011.29.15_suppl.5052"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0019|cit18","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine E Mahner S Kaern J Gebski V Heywood M Vasey P A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG) Journal of Clinical Oncology 2009 ASCO Annual Meeting 2009","DOI":"10.1200\/jco.2009.27.15_suppl.lba5509"},{"issue":"20","key":"10.1002\/14651858.CD006910.pub2-BIB0020|cit19","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0021|cit20","doi-asserted-by":"crossref","unstructured":"Simes R Lee CK Mirza M Sauthier P Georgopoulos A Vergote I The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer. Results from the calypso study Asia-Pacific Journal of Clinical Oncology, 37th Annual Meeting of the Clinical Oncological Society of Australia (COSA) 2010 150-253: Abstr. 262","DOI":"10.1200\/jco.2010.28.15_suppl.5080"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0022|cit21","doi-asserted-by":"crossref","unstructured":"Vasey P A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients European Journal of Cancer, Joint 15th ECCO-34th ESMO Multidiciplinary Congress, Berlin, Germany 2009","DOI":"10.1016\/S1359-6349(09)72053-1"},{"issue":"4","key":"10.1002\/14651858.CD006910.pub2-BIB0023|cit22","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0004|cit23","doi-asserted-by":"crossref","unstructured":"\u00c5vall-Lundqvist E Wimberger P Gladieff L Gebski V Huober JB Floquet A Pegylated liposomal doxorubicin (PLD)-carboplatin (C) (C-D) vs paclitaxel-carboplatin (C-P) in relapsing sensitive ovarian cancer (OC): A 500-patient interim safety analysis of the CALYPSO GCIG Intergroup phase III study Journal of Clinical Oncology 2008 ASCO Annual Meeting 2008","DOI":"10.1200\/jco.2008.26.15_suppl.5565"},{"issue":"31","key":"10.1002\/14651858.CD006910.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","article-title":"Randomized, open-Label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer","volume":"30","author":"Colombo","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006910.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/S0149-2918(03)80172-8","article-title":"Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy","volume":"25","author":"Capri","year":"2003","journal-title":"Clinical therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD006910.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.12-1-72","article-title":"Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients","volume":"12","author":"Coleman","year":"2007","journal-title":"The Oncologist"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0028|cit27","doi-asserted-by":"crossref","unstructured":"Gordon A Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer [abstract] European Journal of Cancer; ECCO Conference 2003","DOI":"10.1016\/S1359-6349(03)90190-X"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0027|cit28","unstructured":"Gordon A Sun S Rackoff W Incidence of adverse events in women (<\/=65 or >65 years) with recurrent ovarian cancer receiving pegylated liposomal doxorubicin or topotecan [abstract] Gynecologic Oncology 2006 60"},{"issue":"14","key":"10.1002\/14651858.CD006910.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006910.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0031|cit31","first-page":"Accessed on 9\/1","article-title":"A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study","volume":"8:3","author":"Bafaloukos","year":"2010","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0032|cit32","unstructured":"Kaye S Kaufman B Lubinski J Matulonis U Gourley C Karlan B Phase II study of the oral parp inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and\/or BRCA2 mutations Annals of Oncology; Proceedings of the 35th ESMO Congress NCT00628251 2010 viii 304"},{"issue":"4","key":"10.1002\/14651858.CD006910.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Vergote IB Colombo N Kutarska E Del Campo J Pippitt C Casado A Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer Journal of Clinical Oncology 2009","DOI":"10.1200\/jco.2009.27.15_suppl.5560"},{"issue":"6","key":"10.1002\/14651858.CD006910.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD006910.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0037|cit37","unstructured":"Mutch DG Orlando M Goss T Wang Y Lilly E Teneriello MG Randomized phase III trial of gemcitabine versus pegylated liposomal doxorubicin for patients with platinum-resistent taxane-pretreated ovarian cancer as second or third line therapy [abstract] Gynecologic Oncology 2006 5"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0038|cit38","unstructured":"O'Byrne KJ Bliss P Graham JD Gerber J Vasey PA Khanna S A phase III study of Doxil\/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer Proceedings of the American Society of Clinical Oncologists 2002 808"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0039|cit39","unstructured":"Bidzinski M Poveda A Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer European Journal of cancer, Supplement, Proceedings of the Joint 15th ECCO - 34th ESMO Multidisciplinary Congress, Berlin 2009 var. pagings"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0040|cit40","unstructured":"Boman K Colombo N Tolerability of trabectedin (TR) plus pegylated liposomal doxorubicin (PLD) in platinum sensitive (p-s) vs. platinum resistant (P-R) patients (PTS) with relapsed ovarian cancer Annals of Oncology; 35th ESMO Congress, Milan, Italy 2010 var. pagings"},{"issue":"8","key":"10.1002\/14651858.CD006910.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdr583","article-title":"Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial","volume":"23","author":"Brundage","year":"2012","journal-title":"Annals of Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006910.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/IGC.0b013e318217b321","article-title":"Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study","volume":"21","author":"Colombo","year":"2011","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0043|cit43","unstructured":"Diebolder H Runnebaum I Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Yondelis) plus pegylated liposomal doxorubicin (Caelyx [PLD]) combination versus PLD alone: Results from a PPS cohort of the OVA-301 phase III study Archives of Gynecology and Obstetrics; 58th Congress of the German Society for Gynaecology and Obstetrics (DGGG) 2010"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Gore M Vergote I Vasanthan S Chan S Arranz JA Colombo N Cost-effectiveness of trabectedin in combination with pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: Analysis based on the final survival data European Journal of Cancer; 2011 ECCO Multidisciplinary Cancer Congress, Stockholm, Sweden 2011","DOI":"10.1016\/S0959-8049(11)72138-4"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Herzog TJ Vermorken JB Pujade-Lauraine E Li J Bayever E Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone [abstract] Journal fo Clinical Oncology; 2009 ASCO Annual Meeting 2009","DOI":"10.1200\/jco.2009.27.15_suppl.5550"},{"issue":"2","key":"10.1002\/14651858.CD006910.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ygyno.2011.04.005","article-title":"Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study","volume":"122","author":"Herzog","year":"2011","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006910.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdq353","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval","volume":"22","author":"Kaye","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Kong B Biakhov M Kelley JL Nunez J Lebedinsky C Parekh TV Influence of tumor control on tumor-related events (TRE) in relapsed ovarian cancer (ROC): results from OVA-301, a randomized phase III study of trabectedin (Tr) with pegylated liposomal doxorubicin (PLD) versus PLD alone [abstract] Journal of Clinical Oncology; 2010 ASCO Annual Meeting 2010","DOI":"10.1200\/jco.2010.28.15_suppl.e15529"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Krasner CN Poveda A Herzog T Vermorken J Monk B Zintl P Health-related quality of life\/patient-reported outcomes in relapsed ovarian cancer: results from a randomized phase III study of trabectedin witj pegylated doxorubicin (PLD) versus PLD alone [abstract] Journal fo Clinical Oncology; 2009 ASCO Annual Meeting 2009","DOI":"10.1200\/jco.2009.27.15_suppl.5526"},{"issue":"1","key":"10.1002\/14651858.CD006910.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2012.06.034","article-title":"Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone","volume":"127","author":"Krasner","year":"2012","journal-title":"Gynecologic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD006910.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/annonc\/mdr001","article-title":"Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study","volume":"22","author":"Kurtz","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0052|cit52","unstructured":"Meerpohl H Tolerability of long-term use of trabectedin in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC) Archives of Gynecology and Obstetrics; 58th Congress of the German Society for Gynaecology and Obstetrics (DGGG) 2010"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0056|cit53","unstructured":"Monk BJ A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC) Annals of Oncology; Joint ECCO 15- 34th ESMO Congress 2009"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0053|cit54","first-page":"(suppl; abstr 5","article-title":"Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer [abstract]","volume":"29","author":"Monk","year":"2011","journal-title":"Journal of Clinical Oncology; 2011 ASCO Annual Meeting"},{"issue":"19","key":"10.1002\/14651858.CD006910.pub2-BIB0054|cit55","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD006910.pub2-BIB0055|cit56","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.ejca.2012.04.001","article-title":"Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis","volume":"48","author":"Monk","year":"2012","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Poveda A Kaye SB McCormack RT Wang S Ricci D Broderick E Circulating tumor cells (CTC) in a study of relapsed\/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD Journal of Clinical Oncology, 2009 ASCO Annual Meeting 2009","DOI":"10.1200\/jco.2009.27.15_suppl.5551"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Poveda A Monk BJ Kaye SB Vermorken JB Nieto A Gomez J Prediction of overall survival (OS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): results from OVA-301 European Journal of cancer, Supplement, Proceedings of the 2011 ECCO Multidisciplinary Congress, Berlin 2011 Abstr:E16 0428","DOI":"10.1200\/jco.2011.29.15_suppl.5067"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Poveda A Monk BJ Kaye SB Vermorken JB Vergote IB Runnebaum IB Prediction of progression-free survival (PFS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): Results from OVA-301 Journal of Clinical Oncology, 2011 ASCO Annual Meeting 2011 (suppl; abstr 5067)","DOI":"10.1200\/jco.2011.29.15_suppl.5067"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0060|cit60","doi-asserted-by":"crossref","unstructured":"Poveda A Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: results from a PPS cohort of a phase III study [abstract] Journal of Clinical Oncology, 2010 ASCO Annual Meeting 2010","DOI":"10.1200\/jco.2010.28.15_suppl.5012"},{"issue":"1","key":"10.1002\/14651858.CD006910.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Romero I Colombo N Kaye SB Arranz J Roszak A Provencher DM Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC) Journal of Clinical Oncology; 2010 ASCO Annual Meeting 2010","DOI":"10.1200\/jco.2010.28.15_suppl.5121"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0063|cit63","unstructured":"Runnebaum IB Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr + PLD) versus PLD alone: Results from a PPS cohort of a phase III study Archives of Gynecology and Obstetrics; 58th Congress of the German Society for Gynaecology and Obstetrics (DGGG) 2010"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0065|cit64","doi-asserted-by":"crossref","unstructured":"Vergote Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older European Journal of cancer, Supplement, Proceedings of the Joint 15th ECCO - 34th ESMO Multidisciplinary Congress, Berlin 2009 var pagings","DOI":"10.1016\/S1359-6349(09)71550-2"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0064|cit65","doi-asserted-by":"crossref","unstructured":"Vergote I Bidzinski M Kelley J Vasanthan S Runnebaum I Vermorken J Health-Related Quality of Life (HRQoL) \/ Patient Reported Outcomes (PRO) of patients with partially platinum sensitive (PPS) recurrent ovarian cancer (ROC) treated in a randomized phase III trial of trabectedin and PLD vs PLD alone (OVA-301): An Exploratory Analysis European Journal of Cancer, Supplement, Proceedings of the 2011 ECCO Multidisciplinary Congress, Berlin 2011 abstr: 8.029","DOI":"10.1016\/S0959-8049(11)72117-7"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Naumann RW Coleman RL Burger RA Herzog TJ Morris R Sausville E PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer Journal of Clinical Oncology 2011","DOI":"10.1200\/jco.2011.29.15_suppl.5045"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0067|cit67","unstructured":"Naumann RW Coleman RL Burger RA Sausville EA Kutarska E Ghaman de SA PRECENDET: A randomised phase II trial comparing EC145 (Vintafolide) and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in patients with platinum-resistant ovarian cancer Unpublished manuscript (submitted to the Journal of Clinical Oncology) 2013 (In press)"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0068|cit68","unstructured":"Naumann RW Symanowski J Kutarska E Sharad G Nashat G De Pasquale S EC20 imaging predicts response in a randomized trial comparing pegylated liposomal doxorubicin (PLD) +\/- EC145 in platinum-resistant ovarian cancer International Journal of Gynaecological Cancer, Proceedings of the 17th International Meeting of ESGO 2011"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Naumann RW Symanowski JT Ghamande SA Gabrail NY Gilbert MG Teneriello G PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer [abstract] Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings 2010","DOI":"10.1200\/jco.2010.28.18_suppl.lba5012b"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0070|cit70","doi-asserted-by":"crossref","unstructured":"Alberts DS Liu PY Wilczynski S Clouser M Lopez A Lange M Phase III randomized trial of pegylated liposomal doxorubicin plus carboplatin versus carboplatin in platinum-sensitive patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: Southwest Oncology Group Protocol S0200 [Abstract] Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1 2007","DOI":"10.1016\/j.ygyno.2007.08.075"},{"issue":"1","key":"10.1002\/14651858.CD006910.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2007.08.075","article-title":"Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)","volume":"108","author":"Alberts","year":"2008","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006910.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2009.11.026","article-title":"Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial","volume":"116","author":"Markman","year":"2010","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Vergote I Finkler N del Campo J Lohr A Hunter J Matei D Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin or topotecan in 3rd-line treatment of platinum refractory or resistant ovarian cancer: phase III study results [Abstract] Journal of Clinical Oncology; 2007 ASCO Annual Meeting 2007","DOI":"10.1200\/jco.2007.25.18_suppl.lba5528"},{"issue":"13","key":"10.1002\/14651858.CD006910.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.ejca.2009.05.016","article-title":"Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer","volume":"45","author":"Vergote","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Cherchi PL Capobianco G Fattorini F Canetto AM Milia L Cosso M Second-line therapy with topotecan and pegylated liposomal doxorubicin vs. topotecan slone in patients with recurrent ovarian cancer International Journal of Gynecological Cancer 2003 IGCS Annual Meeting 2003","DOI":"10.1136\/ijgc-00009577-200303001-00188"},{"issue":"13","key":"10.1002\/14651858.CD006910.pub2-BIB0079|cit76","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1200\/JCO.2009.23.1308","article-title":"Erratum","volume":"27","author":"Bookman","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0080|cit77","doi-asserted-by":"crossref","unstructured":"Bookman MA GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. [Abstract] Journal of Clinical Oncology 2006","DOI":"10.1200\/jco.2006.24.18_suppl.5002"},{"issue":"9","key":"10.1002\/14651858.CD006910.pub2-BIB0076|cit78","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006910.pub2-BIB0077|cit79","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/ijgc-00009577-200311000-00002","article-title":"Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5","volume":"13","author":"Bookman","year":"2003","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0078|cit80","doi-asserted-by":"crossref","unstructured":"Bookman MA Gynecologic Cancer InterGroup (GCIG) GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 2006 5002","DOI":"10.1200\/jco.2006.24.18_suppl.5002"},{"issue":"2 Part 2","key":"10.1002\/14651858.CD006910.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0090-8258(03)00337-8","article-title":"Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5","volume":"90","author":"Copeland","year":"2003","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0082|cit82","unstructured":"Kavanagh JJ Garcia A Choi H Gershenson DM Lewis L Mascavage J Efficacy of TLK286 (Telcyta) alone and Inparaplatin\u00ae or Doxil\u00ae (Caelyx\u00ae) in platinum resistant ovarian cancer - results from 3 phase 2 studies [abstract] International Journal of Gynaecological Cancer 2004 28"},{"issue":"27","key":"10.1002\/14651858.CD006910.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0084|cit84","first-page":"This article is","article-title":"Safety of a 3-weekly schedule of carboplatin plus pegylatedliposomal doxorubicin as first line chemotherapy in patients withovarian cancer: preliminary results of the MITO-2 randomized trial","volume":"6:202","author":"Pignata","year":"2006","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1002\/14651858.CD006910.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000178760","article-title":"Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial","volume":"76","author":"Pignata","year":"2009","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0086|cit86","doi-asserted-by":"crossref","unstructured":"Pignata S Scambia G Savarese A Breda E Sorio R Vernaglia Lombardi A Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO-2 randomized multicenter trial [Abstract] Journal of Clinical Oncology; 2007 ASCO Annual meeting 2007","DOI":"10.1200\/jco.2007.25.18_suppl.5532"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0087|cit87","doi-asserted-by":"crossref","unstructured":"Pignata S Scambia G Savarese A Sorio R Breda E Ferrandina G Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO-2 randomized multicenter trial [abstract] Journal of Clinical Oncology; 2009 ASCO Annual Meeting 2009","DOI":"10.1200\/jco.2009.27.18_suppl.lba5508"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0088|cit88","doi-asserted-by":"crossref","unstructured":"Pignata S Scambia G Savarese A Sorio R Breda E Legge F Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial Journal of Clinical Oncology; 2010 ASCO Annual Meeting 2010","DOI":"10.1200\/jco.2010.28.18_suppl.lba5033"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0089|cit89","doi-asserted-by":"crossref","unstructured":"Pignata S Scambia G Savarese A Sorio R Breda E Legge F Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: The mito-2 (multicentre Italian trials in ovarian cancer) randomized phase III trial Annals of Oncology; 35th ESMO Congress, Milan, Italy 2010","DOI":"10.1200\/jco.2010.28.18_suppl.lba5033"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0090|cit90","doi-asserted-by":"crossref","unstructured":"Pignata S Scambia G Savarese A Zagonel V Gebbia V Scollo P Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO-2 randomized multicenter trial Journal of Clinical Oncology; 2005 ASCO Annual Meeting 2005","DOI":"10.1200\/jco.2005.23.16_suppl.5014"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0091|cit91","doi-asserted-by":"crossref","unstructured":"Palaia I Angioli R Calcagno M Zullo MA Plotti F Basile S Liposome-encapsulated doxorubicin citrate in previously treated recurrent\/metastatic gynecologic malignancies International Journal of Gynecological Cancer 2006","DOI":"10.1111\/j.1525-1438.2007.00825.x"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0092|cit92","unstructured":"Scarfone G Presti M Scarabelli C Polverino GP Polonio N Bertoglio S Pegylated liposomal doxorubicin alone or in combination with platinum compounds in recurrent ovarian cancer after first line chemotherapy containing paclitaxel and carboplatin International Journal of Gynecological Cancer 2006"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0093|cit93","unstructured":"Abbott A trial of ABT-888 in combination with temozolomide versus pegylated liposomal doxorubicin alone in ovarian cancer Accessed on 12\/11\/12 at http:\/\/www.http:\/\/clinicaltrials.gov\/show\/NCT01113957"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0094|cit94","unstructured":"Lai C-H Phase III randomised trial of maintenance pegylated liposomal doxorubicin\/carboplatin versus without in patients with advanced ovarian cancer [Ongoing] Australia and New Zealand Clinical Trials Registry; 2010 Accessed on 20\/11\/12 at http:\/\/www.anzctr.org.au\/ACTRN12607000329460.aspx"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0095|cit95","unstructured":"Kuhn K A Crossover bioequivalence study of intravenously administered ATI0918 and DOXIL\/CAELYX in patients with ovarian cancer Accessed on 14\/11\/12 at ttp:\/\/www.clinicaltrials.gov\/ct2\/show\/record\/NCT01715168"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0096|cit96","unstructured":"Hoffmann-La Roche AURELIA: A study of Avastin (Bevacizumab) added to chemotherapy in patients with platinum-resistant ovarian cancer Accessed on 14\/11\/12 at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00976911"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Meier W Lichtenegger W Marth C Gonzalez-Martin AJ Harter P Tome O Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A planed 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup Study (HECTOR) Journal of Clinical Oncology, 2010 ASCO Annual Meeting 2010","DOI":"10.1200\/jco.2010.28.15_suppl.5071"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Sehouli J Meier W Wimberger P Chekerov R Belau A Mahner S Topotecan plus carboplatin vesus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): a randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR) [abstract] Journal of Clinical Oncology, 2012 ASCO Annual Meeting 2012","DOI":"10.1200\/jco.2012.30.15_suppl.5031"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0099|cit99","unstructured":"ImClone A study of liposomal doxorubicin with or without IMC-3G3 in platinum-refractory or resistant advanced ovarian cancer Accessed on 14\/11\/12 at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00913835"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"McGuire WP Shah GD Loizos N Youssoufian H Rowinsky EK Gore ME Randomized phase II trial of pegylated liposomal doxorubicin (PLD) with or without anti-platelet-derived growth factor receptor-alpha (PDGFR-alpha) monoclonal antibody IMC-3G3 in platinum-refractory\/resistant advanced ovarian cancer Journal of Clinical Oncology 2010","DOI":"10.1200\/jco.2010.28.15_suppl.tps256"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0101|cit101","unstructured":"Colombo N INOVATYON STUDY -International, randomized study in patients with ovarian cancer Accessed on 14\/11\/12 at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01379989"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0102|cit102","unstructured":"NCT00657878 Liposomal doxorubicin versus carboplatin\/paclitaxel in patients with ovarian cancer recurrence between 6 and 12 months after previous platinum based therapy: Phase III randomized multicenter study [Ongoing] Accessed 13\/11\/12 at http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00657878"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0103|cit103","unstructured":"Zeimet A Randomized phase II AGO-study comparing combined liposomal doxorubicin (Myocet) and gemcitabine (Gemzar) with liposomal doxorubicin (Myocet) monotherapy in platinum-refractory and platinum-resistant epithelial cancer of the ovary, fallopian tube and the peritoneum Accessed on 14\/11\/12 at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01100372"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0104|cit104","unstructured":"Monk B VTX-2337 and pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer Accessed on 14\/11\/12 at http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01666444"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0105|cit105","unstructured":"MolMed Phase II study of NGR-hTNF in combination with doxorubicin in platinum-resistant ovarian cancer (NGR018) Accessed on 14\/11\/12 at http:\/\/clinicaltrials.gov\/show\/NCT01358071"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0106|cit106","unstructured":"Endocyte Study for women with platinum resistant ovarian cancer evaluating EC145 in combination with doxil Accessed on 14\/11\/12 at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01170650"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0107|cit107","unstructured":"Sehouli J PROVE A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancer Accessed on 14\/11\/12 at http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01388621"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0108|cit108","unstructured":"Medpace Recruitment Center A randomized, controlled, open-label, phase 2 trial of SGI-110 and carboplatin in subjects with platinum-resistant recurrent ovarian cancer accessed on 14\/11\/12 at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01696032"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0109|cit109","unstructured":"AMGEN Trial IN OVArian cancer-2 Accessed on 14\/11\/12 at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01281254"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0110|cit110","unstructured":"Boehringer Ingelheim Pharmaceuticals Phase II randomized trial of the polo-like kinase 1 inhibitor BI 6727 (Volasertib) monotherapy versus investigator\u00b4s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotoxic therapy Accessed on 12\/11\/12 at http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01121406"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0111|cit111","unstructured":"Janssen-Cilag Pty Ltd CAELYX Product Information http:\/\/www.janssen.com.au\/Products\/Caelyx (Accessed 24 January 2013)"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0112|cit112","unstructured":"CTCAE Common Terminology Criteria for Adverse Events (http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf)"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0113|cit113","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining for heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Healthcare: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Dersimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0115|cit115","unstructured":"Janssen Products Important update regarding the availability of DOXIL http:\/\/www.doxil.com\/sites\/default\/files\/DOXIL_DHCP_letter_July2011.pdf 2011 (Accessed 24\/1\/13)"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0116|cit116","unstructured":"European Medicines Agency EPARs for authorised medicinal products for human use EPARs for authorised medicinal products for human use http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000089\/WC500020173.pdf 2010"},{"issue":"suppl 5","key":"10.1002\/14651858.CD006910.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"v23","DOI":"10.1093\/annonc\/mdq244","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Colombo","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"v61","DOI":"10.1093\/annonc\/mdg754","article-title":"EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary","volume":"14 (Supplement","author":"Sant","year":"2003","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000327767","article-title":"Palmar-plantar erythodysesthesia associated with chemotherapy and its treatment","volume":"4","author":"Podlekareva Farr","year":"2011","journal-title":"Case Reports in Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006910.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2008.12.015","article-title":"Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia","volume":"105","author":"FIGO Committee in Gynecologic Oncology","year":"2009","journal-title":"International Journal of Gynecology and Obstetrics"},{"issue":"2","key":"10.1002\/14651858.CD006910.pub2-BIB0122|cit122","first-page":"223","article-title":"Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet","volume":"7","author":"Gabizon","year":"2001","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD006910.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdr441","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","volume":"23","author":"Gladieff","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0124|cit124","unstructured":"Ferlay J Shin HR Bray F Forman D Mathers C Parkin DM GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide IARC CancerBase No. 10 [Internet] 2010 http:\/\/globocan.iarc.fr"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian Cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"issue":"7414","key":"10.1002\/14651858.CD006910.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0127|cit127","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD006910.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2012.06.033","article-title":"Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership","volume":"127","author":"Maringe","year":"2012","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0129|cit129","first-page":"2099-106","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0130|cit130","first-page":"71","article-title":"Cancer statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"2","key":"10.1002\/14651858.CD006910.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemel","year":"2011","journal-title":"CA Cancer Journal"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1756-8722-3-9","article-title":"Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer","volume":"3","author":"Kavanagh","year":"2010","journal-title":"Journal of Hematology & Oncology; www.jhoonline.org\/content\/3\/1\/9"},{"issue":"7","key":"10.1002\/14651858.CD006910.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erthrodysesthesia ('hand-foot syndrome')","volume":"18","author":"Lorusso","year":"2007","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2007.10.021","article-title":"Prevention strategies in palmar-plantar erythodysesthesia onset: the role of regional cooling","volume":"108","author":"Mangili","year":"2008","journal-title":"Gynecologic Oncology"},{"issue":"19","key":"10.1002\/14651858.CD006910.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1200\/JCO.2010.28.9934","article-title":"Serious ethical dilemma of single-agent peylyated liposomal doxorubin employed as a control arm in ovarian cancer chemotherapy trials","volume":"28","author":"Markman","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD006910.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD006910.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.ejca.2012.04.001","article-title":"Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis","volume":"48","author":"Monk","year":"2012","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0139|cit139","unstructured":"National Institute for Clinical Excellence Guidance on the use of paclitaxel in the treatment of ovarian cancer NICE: Technology Appraisal Guidance- No. 55 2003"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0140|cit140","unstructured":"National Institute for Health and Clinical Excellence Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (review) www.nice.org.uk\/nicemedia\/live\/11554\/33026\/33026.pdf 2005 1 4"},{"issue":"24","key":"10.1002\/14651858.CD006910.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"2 Suppl 6","key":"10.1002\/14651858.CD006910.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.seminoncol.2006.03.012","article-title":"Management of platinum-sensitive recurrent ovarian cancer","volume":"33","author":"Pfisterer","year":"2006","journal-title":"Seminars in Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006910.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0144|cit144","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) [Computer program]. Version 5.2 2012"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1634\/theoncologist.10-3-205","article-title":"Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer","volume":"10","author":"Rose","year":"2005","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study","volume":"7","author":"Rustin","year":"1996","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0147|cit147","first-page":"133","article-title":"Chapter 16: Cancer of the ovary","volume-title":"Cancer Survival Among Adults: US SEER Program, 1988-2001","author":"Kosary","year":"2007"},{"issue":"10","key":"10.1002\/14651858.CD006910.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.20207","article-title":"Cardiac profiles of liposomal anthracyclines","volume":"100","author":"Theodoulou","year":"2004","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumours: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"Moos","year":"2008","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD006910.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006910.pub2-BIB0152|cit152","first-page":"715","article-title":"Antitumour Antibodies","volume-title":"Oxford Textbook of Oncology","author":"Zunino","year":"2002"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006910.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006910.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T20:05:35Z","timestamp":1688328335000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006910.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,9]]},"references-count":152,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006910.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718028212.793483427","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718028212.793484797","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,9]]}}}